
PEARQ
Healthcare · Health Information Services · $142 market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2022
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 24, 2024 | Before the open | -0.11 | 0.00 | +100.0% |
| Nov 3, 2023 | Before the open | -0.13 | 0.00 | +100.0% |
| Aug 11, 2023 | Time not confirmed | -0.14 | 0.00 | +100.0% |
| May 15, 2023 | Time not confirmed | -0.18 | 0.00 | +100.0% |
| Mar 31, 2023 | After the close | -0.22 | -0.19 | +13.2% |
| Nov 14, 2022 | Time not confirmed | -0.21 | -0.22 | -4.8% |
| Aug 11, 2022 | Time not confirmed | -0.21 | 0.04 | +119.0% |
| May 16, 2022 | Time not confirmed | -0.24 | -0.17 | +27.8% |
| Mar 28, 2022 | Time not confirmed | -0.41 | 0.13 | +131.7% |
| Dec 1, 2021 | Time not confirmed | -0.23 | -0.23 | 0.0% |
| Aug 19, 2021 | Time not confirmed | — | -0.27 | — |
| May 24, 2021 | Time not confirmed | — | 0.06 | — |
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines in the United States. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The…